Effect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in multiple sclerosis: study protocol for a randomised, controlled trial.

Herr, Thorsten; Penner, Iris-Katharina; Weymar, Mathias; Szeska, C.; Grothe, M.; Strauss, S.; Flöel, Agnes; Gamain, Julie

doi:10.1136/bmjopen-2025-103998

Items
Marc 21

001			281916
005			20260105130530.0
024	7	_	\|a 10.1136/bmjopen-2025-103998 \|2 doi
024	7	_	\|a pmid:41213698 \|2 pmid
024	7	_	\|a pmc:PMC12598993 \|2 pmc
037	_	_	\|a DZNE-2025-01258
041	_	_	\|a English
082	_	_	\|a 610
100	1	_	\|a Herr, Thorsten \|0 0009-0008-6844-1968 \|b 0
245	_	_	\|a Effect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in multiple sclerosis: study protocol for a randomised, controlled trial.
260	_	_	\|a London \|c 2025 \|b BMJ Publishing Group
336	7	_	\|a article \|2 DRIVER
336	7	_	\|a Output Types/Journal article \|2 DataCite
336	7	_	\|a Journal Article \|b journal \|m journal \|0 PUB:(DE-HGF)16 \|s 1762942687_29014 \|2 PUB:(DE-HGF)
336	7	_	\|a ARTICLE \|2 BibTeX
336	7	_	\|a JOURNAL_ARTICLE \|2 ORCID
336	7	_	\|a Journal Article \|0 0 \|2 EndNote
520	_	_	\|a Research in people with relapsing remitting multiple sclerosis (PwRRMS) is increasingly focusing on non-motor symptoms like cognitive impairment, fatigue and depression. Due to the high negative impact on quality of life and high socioeconomic costs based on these symptoms, more specific research to improve non-motor symptoms is needed. Transcutaneous auricular vagus nerve stimulation (taVNS) has been found to be a cognitive enhancer in preclinical research and was successfully used for the treatment of psychiatric and neurological disorders to combat dysfunctional cognitive and affective processes. However, the capacity of taVNS to improve cognitive and other non-motor symptoms in PwRRMS has not been tested yet. The aim of this study is to evaluate the therapeutic potential of taVNS on cognitive processing speed. Based on ample evidence demonstrating that taVNS promotes adaptive cognitive and affective processes, we hypothesised that taVNS would alleviate cognitive processing speed in PwRRMS.This study protocol describes the prospective, single-centre, SHAM-controlled, single-blinded trial with a planned sample size of 60 participants (30 PwRRMS, with a diagnosis of multiple sclerosis according to McDonald criteria and 30 healthy controls; age: 18-50 years). The Symbol Digit Modalities Test (SDMT) will be used to determine cognitive processing speed, Beck Depression Inventory-II to determine depression and Fatigue Scale for Motor and Cognitive Functions to determine fatigue. The severity of multiple sclerosis will be assessed using the Expanded Disability Status Scale. After baseline assessment, a taVNS protocol (duration: 30 min, tolerance threshold, pulse width: 250 μs, stimulation frequency: 25 Hz, 30 s on/30 s off) will be applied, followed by post-intervention assessment.The study was reviewed and approved by the local ethics committee of the University Medical Centre Greifswald (study reference number: BB137/24).www.drks.de, number: DRKS00034912. Study results will be disseminated through academic conferences as well as peer-reviewed publications.DRKS00034912.
536	_	_	\|a 353 - Clinical and Health Care Research (POF4-353) \|0 G:(DE-HGF)POF4-353 \|c POF4-353 \|f POF IV \|x 0
588	_	_	\|a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650	_	7	\|a Multiple sclerosis \|2 Other
650	_	7	\|a NEUROPHYSIOLOGY \|2 Other
650	_	7	\|a Neurophysiology \|2 Other
650	_	2	\|a Humans \|2 MeSH
650	_	2	\|a Vagus Nerve Stimulation: methods \|2 MeSH
650	_	2	\|a Single-Blind Method \|2 MeSH
650	_	2	\|a Multiple Sclerosis, Relapsing-Remitting: therapy \|2 MeSH
650	_	2	\|a Multiple Sclerosis, Relapsing-Remitting: psychology \|2 MeSH
650	_	2	\|a Multiple Sclerosis, Relapsing-Remitting: complications \|2 MeSH
650	_	2	\|a Transcutaneous Electric Nerve Stimulation: methods \|2 MeSH
650	_	2	\|a Prospective Studies \|2 MeSH
650	_	2	\|a Quality of Life \|2 MeSH
650	_	2	\|a Adult \|2 MeSH
650	_	2	\|a Depression: therapy \|2 MeSH
650	_	2	\|a Depression: etiology \|2 MeSH
650	_	2	\|a Female \|2 MeSH
650	_	2	\|a Fatigue: therapy \|2 MeSH
650	_	2	\|a Fatigue: etiology \|2 MeSH
650	_	2	\|a Male \|2 MeSH
650	_	2	\|a Randomized Controlled Trials as Topic \|2 MeSH
650	_	2	\|a Cognitive Dysfunction: therapy \|2 MeSH
650	_	2	\|a Cognitive Dysfunction: etiology \|2 MeSH
650	_	2	\|a Middle Aged \|2 MeSH
650	_	2	\|a Treatment Outcome \|2 MeSH
650	_	2	\|a Cognition \|2 MeSH
700	1	_	\|a Gamain, Julie \|b 1
700	1	_	\|a Strauss, S. \|b 2
700	1	_	\|a Szeska, C. \|b 3
700	1	_	\|a Flöel, Agnes \|0 P:(DE-2719)2812683 \|b 4
700	1	_	\|a Penner, Iris-Katharina \|b 5
700	1	_	\|a Weymar, Mathias \|0 0000-0002-3968-9656 \|b 6
700	1	_	\|a Grothe, M. \|b 7
773	_	_	\|a 10.1136/bmjopen-2025-103998 \|g Vol. 15, no. 11, p. e103998 - \|0 PERI:(DE-600)2599832-8 \|n 11 \|p e103998 \|t BMJ open \|v 15 \|y 2025 \|x 2044-6055
856	4	_	\|y OpenAccess \|u https://pub.dzne.de/record/281916/files/DZNE-2025-01258.pdf
856	4	_	\|y OpenAccess \|x pdfa \|u https://pub.dzne.de/record/281916/files/DZNE-2025-01258.pdf?subformat=pdfa
909	C	O	\|o oai:pub.dzne.de:281916 \|p openaire \|p open_access \|p VDB \|p driver \|p dnbdelivery
910	1	_	\|a Deutsches Zentrum für Neurodegenerative Erkrankungen \|0 I:(DE-588)1065079516 \|k DZNE \|b 4 \|6 P:(DE-2719)2812683
913	1	_	\|a DE-HGF \|b Gesundheit \|l Neurodegenerative Diseases \|1 G:(DE-HGF)POF4-350 \|0 G:(DE-HGF)POF4-353 \|3 G:(DE-HGF)POF4 \|2 G:(DE-HGF)POF4-300 \|4 G:(DE-HGF)POF \|v Clinical and Health Care Research \|x 0
914	1	_	\|y 2025
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0200 \|2 StatID \|b SCOPUS \|d 2024-12-19
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0160 \|2 StatID \|b Essential Science Indicators \|d 2024-12-19
915	_	_	\|a Creative Commons Attribution CC BY 4.0 \|0 LIC:(DE-HGF)CCBY4 \|2 HGFVOC
915	_	_	\|a JCR \|0 StatID:(DE-HGF)0100 \|2 StatID \|b BMJ OPEN : 2022 \|d 2024-12-19
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0501 \|2 StatID \|b DOAJ Seal \|d 2024-01-24T13:10:16Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0500 \|2 StatID \|b DOAJ \|d 2024-01-24T13:10:16Z
915	_	_	\|a WoS \|0 StatID:(DE-HGF)0113 \|2 StatID \|b Science Citation Index Expanded \|d 2024-12-19
915	_	_	\|a Fees \|0 StatID:(DE-HGF)0700 \|2 StatID \|d 2024-12-19
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0150 \|2 StatID \|b Web of Science Core Collection \|d 2024-12-19
915	_	_	\|a IF < 5 \|0 StatID:(DE-HGF)9900 \|2 StatID \|d 2024-12-19
915	_	_	\|a OpenAccess \|0 StatID:(DE-HGF)0510 \|2 StatID
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b DOAJ : Open peer review \|d 2024-01-24T13:10:16Z
915	_	_	\|a Article Processing Charges \|0 StatID:(DE-HGF)0561 \|2 StatID \|d 2024-12-19
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0300 \|2 StatID \|b Medline \|d 2024-12-19
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0199 \|2 StatID \|b Clarivate Analytics Master Journal List \|d 2024-12-19
920	1	_	\|0 I:(DE-2719)5000081 \|k AG Flöel \|l Dementia Prevention – Mechanisms and Clinical Implementation \|x 0
980	_	_	\|a journal
980	_	_	\|a VDB
980	_	_	\|a UNRESTRICTED
980	_	_	\|a I:(DE-2719)5000081
980	1	_	\|a FullTexts

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

guest :: login DZNEPUB
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help